Aspire BioPharma, Inc. (ASBP) - Total Liabilities
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has total liabilities worth $3.25 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ASBP working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Aspire BioPharma, Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aspire BioPharma, Inc. assets under control.
Aspire BioPharma, Inc. Competitors by Total Liabilities
The table below lists competitors of Aspire BioPharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
USA | $45.60 Million |
|
Victrex plc
LSE:VCT
|
UK | GBX135.70 Million |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
India | Rs-2.76 Billion |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
Indonesia | Rp1.10 Trillion |
|
Companhia de Fiacao e Tecidos Cedro Cachoeira
SA:CEDO3
|
Brazil | R$665.75 Million |
|
Zyrexindo Mandiri Buana PT Tbk
JK:ZYRX
|
Indonesia | Rp496.67 Billion |
|
Iconic Minerals Ltd
V:ICM
|
Canada | CA$683.50K |
|
elumeo SE
XETRA:ELB
|
Germany | €15.03 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Aspire BioPharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ASBP equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aspire BioPharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual total liabilities of Aspire BioPharma, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.69 Million | +355.46% |
| 2024-12-31 | $1.69 Million | +318.54% |
| 2023-12-31 | $403.33K | -96.37% |
| 2022-12-31 | $11.12 Million | +3684.81% |
| 2021-12-31 | $293.70K | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more